If you're worried about gallstones, a new study suggests paying attention to your metabolic health might be more important than you think. Researchers followed over 52,000 people without gallstones for an average of about three years. They tracked a score called METS-IR, which measures your body's resistance to insulin—a key hormone for managing blood sugar and metabolism. They found a surprising 'U-shaped' relationship between this score and gallstone risk. The risk was lowest when the METS-IR score was around 29.83. For people with scores below that point, each unit increase in the score was actually linked to a slightly lower risk of gallstones. But for people with scores above that point, each unit increase was linked to a higher risk. In fact, people in the highest-scoring group had nearly double the risk compared to those in the second-lowest group. The study found this pattern held true across different groups of people, making the finding robust. This means that for gallstone prevention, having a metabolic score that's too low or too high might both be problematic, pointing to a specific 'sweet spot' for metabolic health.
Could your body's insulin resistance score reveal your risk for gallstones? A new study finds a surprising U-shaped link.
Photo by Kedibone Isaac Makhumisane / Unsplash
What this means for you:
Your metabolic health score has a U-shaped link to gallstone risk—being too high or too low is associated with higher risk. More on Insulin Resistance
Narrative review links microgravity exposure to altered fat distribution and inflammation in metabolic disease models. How Space Travel Is Unlocking New Ways to Fight Obesity and Diabetes
Frontiers · Apr 24, 2026
IGFBP2 as a context-dependent regulator of metabolic dysregulation in obesity and type 2 diabetes IGFBP2 may signal metabolic changes in obesity and diabetes, but human proof is still missing.
Frontiers · Apr 21, 2026
Narrative review explores adipose tissue macrophage regulation for obesity and metabolic disorders The Immune Cells Inside Fat Tissue That Drive Obesity's Hidden Damage
Frontiers · Apr 18, 2026
Phase II RCT: Amiloride reduces arterial stiffness and blood pressure in adults with obesity and metabolic syndrome Low-dose amiloride reduced arterial stiffness and blood pressure in adults with obesity
· Apr 8, 2026